Skip to content

Double-blind, randomized and placebo-controlled clinical trial on the efficacy and safety on hair loss prevention for 24 weeks

Double-blind, randomized and placebo-controlled clinical trial on the efficacy and safety of M-200729327-01,02 on hair loss prevention for 24 weeks

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0005618
Enrollment
60
Registered
2020-11-23
Start date
2020-09-14
Completion date
Unknown
Last updated
2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Others : During the test period, volunteers are washed their scalp and hair using the provided standard shampoo and conditioner and dry them completely. According to the randomization and double-blind

Sponsors

Ellead
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: ? 18~54 years old men and women diagnosed with androgenic alopecia. ? Androgenic alopecia patients who have been diagnosed as basic type M2, C2, U1 or above, or specific type V1, F1 or above based on Basic and specific (BASP) classification for men and women, stage 3 or above on Norwood-Hamilton scale for men, and stage 1 or above on Ludwig scale for women ? Those who do not use special hair growth products and receive hair care and surgical procedure during study period. ? Those who are willing to maintain the same hair style, length, and color during the study period.

Exclusion criteria

Exclusion criteria: ? Those who have suffered acute renal, cardiac, or other chronic disease (hypertension or diabetes) that can affect the study results within 6 months. ? Those who are pregnant, breast feeding or planning pregnancy within the last 6 months. ? Those who have mental disorder. ? Those who have infectious skin disease. ? Those who received surgical treatments or procedures such as hair transplant or scalp reduction. ? Those who have used oral, dutasteride or finasteride within the last 6 months. ? Those who have applied topical hair growth products or hair tonic to the scalp within the last 1 month. ? Those who have used the following drugs within the last 1 month: steroids, apoptotic agents, vasodilators, antihypertensive drugs, antiepileptics, beta receptor blocker, bronchodilator, diuretic, spironolactone, cimetidine, diazoxide, cyclosporine, and ketoconazole. ? Those who have applied topical steroids to scalp within the last 1 months. ? Those who have been judged to have difficulty in applying the test product to the scalp because of severe seborrheic dermatitis, psoriasis, and infection of scalp. ? Those who have other type of alopecia such as alopecia areata, telogen effluvium, and alopecia cicatrisata besides androgenic alopecia. ? Those who have been judged by the study director to be unsuitable for enrollment in this clinical trial.

Design outcomes

Primary

MeasureTime frame
the number of hair in test area

Secondary

MeasureTime frame
Visual assessment according to the BASP classification by Expert

Countries

Korea, Republic of

Contacts

Public Contacthoyoung Jung

Ellead

hoyoung0410@ellead.co.kr+82-31-709-9070

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026